



For immediate release

PRESS RELEASE

BIOPHAGE PHARMA APPOINTS DR. PEARL CHIN TO BOARD OF DIRECTORS

*Dr. Chin is Leading Authority on Nanotechnology and is
Managing Director of Seraphima Ventures*

Montreal, October 4, 2005 – (TSX.V: BUG). Biophage Pharma is pleased to announce the appointment of Dr. Pearl Chin to its Board of Directors. Dr. Chin is the founder and Managing Director of Seraphima Ventures. Dr Chin will fill the vacancy created by the departure of Mr. Bruce Schmidt from his administrative responsibilities.

Dr. Chin specializes in advising on nanotechnology investment opportunities. She has extensive experience in strategy and marketing consulting, management consulting, operations, sales and marketing, and customer service, in diverse industries from small to large companies. She was Managing Director of the US offices and co-Managing Director of the London offices of Cientifica, a global nanotechnology consultancy providing business information, marketing analyses and business strategy consulting to Fortune 500 companies and investment firms.

Dr. Chin stated, “Biophage Pharma represents an excellent example of the potential of nanotechnology in the management of human health. Biophage Nanosensors is just beginning to harness the power that nanotechnology can bring to new product development. My years of experience in this field will help guide the company in the years ahead and advance their products to commercial breakthrough”.

“I am very pleased that such a prestigious expert in the field of Nanotechnology has decided to join our Board of Directors. She brings extensive knowledge and entrepreneurial experience in the field of nanotechnology. Her expertise and industry contacts will be an invaluable resource for the advancement of our company,” said Dr. Rosemonde Mandeville, President and Chief Executive Officer of Biophage Pharma. “I would like to extend my sincere gratitude to the excellent work that Mr. Bruce Schmidt has contributed to the Corporation through all the years that he has worked with us”, added Dr Mandeville.

Biophage is also pleased to announce that Mr. Benoit Morel from the Law Firm Desjardins Ducharme has been appointed Corporate Secretary. Mr Morel is also President of the Quebec Association of MBAs.

About Biophage Pharma Inc.

Biophage Pharma Inc. is a Canadian biopharmaceutical company developing novel products based on the unique properties of phages. Founded in 1995, Biophage is located at the Biotechnology Research Institute in Montreal and employs 15 people, including a team of 13 researchers. Through an active research and development program, the increasing revenue generated by its CRO division, as well as in-licensing and collaboration agreements, Biophage is building a portfolio of promising new diagnostic tools based on nanosensor technologies and focused on the rapid detection of pathogens and their toxins including those used as BWA agents. Additional information about our bacteriophage and nanosensor platforms can be found at our website www.biophage.com.

Information:

Rosemonde Mandeville, M.B. Ch.B., Ph.D.
President and Chief Executive Officer
Biophage Pharma Inc.
(514) 496-1488
info@biophagepharma.com

Stuart Fine
Investor Relations
Carpe DM, Inc.
(908) 490-0075
stuart@carpedminc.com

Christine Stewart
Account Manager
Investor Relations
Renmark Financial Communications Inc.
(514) 939-3989
cstewart@renmarkfinancial.com